Cargando…

Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014

BACKGROUND: Kaposi's sarcoma (KS) is the most prevalent HIV and AIDS-associated cancer in the world. Zambia has been considered as part of the “KS belt”, where endemic KS has been prevalent. This study, therefore, aimed to present the descriptive epidemiology of Kaposi's sarcoma in Zambia...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalubula, Maybin, Shen, Heqing, Makasa, Mpundu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Medical Association Of Malawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788595/
https://www.ncbi.nlm.nih.gov/pubmed/35140843
http://dx.doi.org/10.4314/mmj.v32i2.4
_version_ 1784639602204606464
author Kalubula, Maybin
Shen, Heqing
Makasa, Mpundu
author_facet Kalubula, Maybin
Shen, Heqing
Makasa, Mpundu
author_sort Kalubula, Maybin
collection PubMed
description BACKGROUND: Kaposi's sarcoma (KS) is the most prevalent HIV and AIDS-associated cancer in the world. Zambia has been considered as part of the “KS belt”, where endemic KS has been prevalent. This study, therefore, aimed to present the descriptive epidemiology of Kaposi's sarcoma in Zambia from 2007 – 2014. METHODS: We conducted the descriptive epidemiology of Kaposi's sarcoma in Zambia nested on two data sources; the Zambia National Cancer Registry (ZNCR) Kaposi's sarcoma (KS) data, and population-based HIV data from the Zambia National AIDS Council (NAC). Central Statistics Office (CSO) demographic data were used to determine the prevalence and annual incidence of KS. KS sample was 2521while HIV data from NAC were already population-based (HIV impact assessment survey). We used Microsoft Excel and SPSS version 21 in graphical computation and statistical analyses. RESULTS: Both HIV and KS were highly prevalent in Lusaka, Central, and Southern provinces. ART coverage ranged from 40% – 60%; HIV prevalence was 14.9% in females and 9.5% in males while KS prevalence was 13/100,000 in females and 21/100,000 in males. HIV prevalence was associated with KS prevalence with r = 0.827 and a p-value of 0.001 in males, and r = 0.898 with a p-value of 0.000 in females. There were 61% confirmed HIV seropositive KS, 18% confirmed HIV seronegative KS and 21% unknown HIV status KS. CONCLUSION: The high prevalence of KS in Zambia is as a result of the high prevalence of HIV. The identified two key interventions for the reduction of KS morbidity are; reducing HIV infection rate and improving ART coverage across the country.
format Online
Article
Text
id pubmed-8788595
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Medical Association Of Malawi
record_format MEDLINE/PubMed
spelling pubmed-87885952022-02-08 Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014 Kalubula, Maybin Shen, Heqing Makasa, Mpundu Malawi Med J Original Research BACKGROUND: Kaposi's sarcoma (KS) is the most prevalent HIV and AIDS-associated cancer in the world. Zambia has been considered as part of the “KS belt”, where endemic KS has been prevalent. This study, therefore, aimed to present the descriptive epidemiology of Kaposi's sarcoma in Zambia from 2007 – 2014. METHODS: We conducted the descriptive epidemiology of Kaposi's sarcoma in Zambia nested on two data sources; the Zambia National Cancer Registry (ZNCR) Kaposi's sarcoma (KS) data, and population-based HIV data from the Zambia National AIDS Council (NAC). Central Statistics Office (CSO) demographic data were used to determine the prevalence and annual incidence of KS. KS sample was 2521while HIV data from NAC were already population-based (HIV impact assessment survey). We used Microsoft Excel and SPSS version 21 in graphical computation and statistical analyses. RESULTS: Both HIV and KS were highly prevalent in Lusaka, Central, and Southern provinces. ART coverage ranged from 40% – 60%; HIV prevalence was 14.9% in females and 9.5% in males while KS prevalence was 13/100,000 in females and 21/100,000 in males. HIV prevalence was associated with KS prevalence with r = 0.827 and a p-value of 0.001 in males, and r = 0.898 with a p-value of 0.000 in females. There were 61% confirmed HIV seropositive KS, 18% confirmed HIV seronegative KS and 21% unknown HIV status KS. CONCLUSION: The high prevalence of KS in Zambia is as a result of the high prevalence of HIV. The identified two key interventions for the reduction of KS morbidity are; reducing HIV infection rate and improving ART coverage across the country. The Medical Association Of Malawi 2020-06 /pmc/articles/PMC8788595/ /pubmed/35140843 http://dx.doi.org/10.4314/mmj.v32i2.4 Text en © 2020 The College of Medicine and the Medical Association of Malawi. https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Original Research
Kalubula, Maybin
Shen, Heqing
Makasa, Mpundu
Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014
title Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014
title_full Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014
title_fullStr Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014
title_full_unstemmed Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014
title_short Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014
title_sort epidemiology of kaposi's sarcoma in zambia, 2007 – 2014
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788595/
https://www.ncbi.nlm.nih.gov/pubmed/35140843
http://dx.doi.org/10.4314/mmj.v32i2.4
work_keys_str_mv AT kalubulamaybin epidemiologyofkaposissarcomainzambia20072014
AT shenheqing epidemiologyofkaposissarcomainzambia20072014
AT makasampundu epidemiologyofkaposissarcomainzambia20072014